Table 2.
Echocardiographic and laboratory values of patients presenting before and after sacubitril/valsartan (LCZ696)
| Variables | Before LCZ696 | 3 months after LCZ696 | 6 months after LCZ696 | 12 months after LCZ696 | 18 months after LCZ696 | 24 months after LCZ696 | P valuea |
|---|---|---|---|---|---|---|---|
| Echocardiographic values | |||||||
| LVEF, % | 28 (3; 65) | 34 (5; 69) | 33 (15; 60) | 33.5 (13; 60) | 33 (15; 58) | 34 (13; 64) | <0.001 |
| TAPSE, mm | 17 (3; 31) | 18 (8; 38) | 18 (2.3; 32) | 20 (9; 30) | 19 (2.1; 42) | 18 (2.5; 31) | 0.01 |
| PAPsys, mmHg | 30 (13; 115) | 30.5 (15; 68) | 30 (11; 71) | 29 (10; 88) | 25 (12; 73) | 25 (20; 80) | 0.02 |
| TR dPmax, mmHg | 30.5 (13; 101) | 36.5 (14; 68) | 35 (17; 71) | 30 (2; 87) | 30.4 (14; 57) | 29 (25; 75) | 0.69 |
| TR Vmax, m/s | 2.75 (0.7; 4.5) | 3.11 (2.4; 4.13) | 2.8 (0.95; 4.2) | 3.0 (1.8; 5.0) | 2.85 (3; 3) | 2.8 (1.7; 7.0) | 0.81 |
| LA, cm2 | 25 (12; 63) | 25 (14; 48) | 23 (11; 57) | 23 (11; 58) | 24 (11; 43) | 24 (12; 56) | 0.65 |
| RA, cm2 | 19 (7; 44) | 17 (8; 39) | 18.25 (8; 40) | 18.6 (7; 40) | 19 (8.1; 35) | 17 (7; 41) | 0.74 |
| VCI diameter, mm | 20 (3; 40) | 17 (13; 29) | 20 (9; 28) | 17 (7; 40) | 21 (7; 34) | 19 (12; 35) | 0.88 |
| E/A ratio | 1.3 (0.49; 3.8) | 0.87 (0.36; 3.86) | 0.8 (0.3; 3.6) | 0.9 (0.4; 5.8) | 0.9 (0.44; 2.8) | 0.8 (0.4; 2.3) | 0.05 |
| NYHA classification | |||||||
| I | 8/208 (3.8) | 17/185 (9.2) | 21/169 (12.4) | 24/157 (15.3) | 22/130 (16.9) | 25/118 (21.2) | < 0.001 |
| II | 55/208 (26.4) | 68/185 (36.8) | 68/169 (40.2) | 67/157 (42.7) | 60/130 (46.2) | 53/118 (44.9) | < 0.001 |
| III | 124/208 (59.6) | 84/185 (45.4) | 71/169 (42.0) | 61/157 (38.9) | 44/130 (33.8) | 37/118 (31.4) | < 0.001 |
| IV | 21/208 (10.1) | 16/185 (8.6) | 9/169 (5.3) | 5/157 (3.2) | 4/130 (3.1) | 3/118 (2.5) | < 0.001 |
| Laboratory values | |||||||
| Potassium, mmol/l | 4.15 (2.1; 6.5) | 4.23 (2.9; 6.0) | 4.3 (2.7; 4.6) | 4.21 (2.86; 5.7) | 4.30 (2.38; 6.6) | 4.23 (2.8; 5.5) | 0.69 |
| Creatinine, mg/dl | 1.20 (0.34; 6.95) | 1.31 (0.58; 3.37) | 1.28 (0.68; 7.02) | 1.32 (0.65; 4.9) | 1.34 (0.67; 4.40) | 1.25 (0.56; 7.63) | 0.23 |
| GFR, ml/min | 55.0 (10; 128.8) | 51.0 (21; 117) | 50.0 (3; 128.8) | 51.0 (11; 102) | 48.0 (15; 125) | 49.0 (8; 109) | < 0.001 |
| TNI, ng/ml | 0.077 (0.009; 138.690) | 0.021 (0.002; 0.600) | 0.048 (0.013; 0.878) | 0.015 (0.005; 14.945) | 0.019 (0.015; 0.208) | 0.020 (0.006; 0.635) | 0.13 |
| NT-proBNP, pg/ml | 1445.0 (48; 74,676) | 1149.5 (31; 15,505) | 991.5 (78; 26,041) | 770.5 (49; 8598) | 813 (30; 8634) | 569 (13; 4571) | < 0.001 |
| Hb, g/dl | 13.8 (8.2; 17.8) | 13.5 (8.3; 18.3) | 13.6 (9.3; 17.6) | 13.6 (7.1; 17.2) | 13.6 (8.0; 17.2) | 14.0 (8.7; 17.1) | 0.83 |
| HbA1c, % | 6.0 (4.3; 11.5) | 6.4 (5.2; 12.2) | 6.6 (5.3; 11.7) | 6.1 (5.2; 14.4) | 6.3 (5.0; 11.2) | 6.2 (5.2; 9.9) | 0.68 |
Data are presented as n (%) or median (minimum; maximum)
Bold text indicates a statistically significant difference with a p-value less than 0.05
E/A ratio E wave/A wave ratio, GFR glomerular filtration rate, Hb hemoglobin, HbA1c glycated Hb, LA left atrial surface, LCZ696 sacubitril/valsartan, LVEF left ventricular ejection fraction, n number, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New York Heart Association, PAPsys systolic pulmonary arterial pressure, RA right atrial surface, TAPSE tricuspid annular plane systolic excursion, TNI high-sensitivity troponin I, TR dPmax tricuspid regurgitation jet maximal pressure gradient, TR Vmax tricuspid regurgitation peak velocity, VCI vena cava inferior
ap values for the comparison between before and all times after sacubitril/valsartan, p values for pairwise comparisons are presented in the electronic supplementary material